Results 91 to 100 of about 351 (170)

Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity. [PDF]

Front Pharmacol
Jiang H, Che J.
europepmc   +1 more source

Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models. [PDF]

Oncotarget, 2022
Ghazal D, Zalzala F, Fisk JC, Tati S, Karacosta LG, Morey S, Olson JR, Quataert S, Dy GK, Rittenhouse-Olson K.   +9 more
europepmc   +1 more source

The genetic architecture of resistance to septoria tritici blotch in French wheat cultivars. [PDF]

BMC Plant Biol
Thauvin JN, Gélisse S, Cambon F, Langin T, Breedwheat consortium, Marcel TC, Saintenac C.   +6 more
europepmc   +1 more source

Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies. [PDF]

Drug Deliv
Feng C, Lou R, Chen S, Lin F, Ge J, Zhang Y, Lin C, Huang C.   +7 more
europepmc   +1 more source

Synergistic Nitrogen Removal and Community Interaction Mechanism of Immobilized Bacteria Algae Symbiosis System. [PDF]

Molecules
Song J, Xu P, Wei Z, Yao H, Wang A, Xu C, Zhu Y, Wang R, Yuan X.   +8 more
europepmc   +1 more source

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. [PDF]

Front Pharmacol, 2021
Chen Z, Yuan J, Xu Y, Zhang C, Li Z, Gong J, Li Y, Shen L, Gao J.   +8 more
europepmc   +1 more source

Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives. [PDF]

Front Pharmacol
Shi X, Tang K, Zhang Q, Han Q, Quan L, Li Y, Cui J, Feng N, Gong J, Shang B, Li X.   +10 more
europepmc   +1 more source

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer. [PDF]

Cancer Res Treat
Ma L, Zheng R, Xu L, Zhu Y, Yin H, Zhang X, Deng R, Wang J, Zha X.   +8 more
europepmc   +1 more source

Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells. [PDF]

Drug Metab Dispos, 2020
Sharma S, Li Z, Bussing D, Shah DK.
europepmc   +1 more source

Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential. [PDF]

Oncol Res
Vo TH, McNeela E, O'Donnovan O, Prakash Mehta J, Nguyen VH, Rani S.   +5 more
europepmc   +1 more source